{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:13:59Z","timestamp":1790079239882,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ijantimicag.2016.11.020","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T20:42:04Z","timestamp":1485290524000},"page":"542-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes"],"prefix":"10.1016","volume":"49","author":[{"given":"Keith S.","family":"Kaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-768X","authenticated-orcid":false,"given":"Ana C.","family":"Gales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Dubourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0010","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0015","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0025-6196(11)65134-3","article-title":"The aminoglycosides","volume":"74","author":"Edson","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0020","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0924-8579(03)00245-0","article-title":"Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997\u20132001)","volume":"22","author":"Jones","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0025","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2015.06.011","article-title":"Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010\u20132013)","volume":"83","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0030","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0035","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0040","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1469-0691.12697","article-title":"Treating infections caused by carbapenemase-producing Enterobacteriaceae","volume":"20","author":"Tzouvelekis","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0045","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0050","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/jac\/dku432","article-title":"Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae","volume":"70","author":"Gonzalez-Padilla","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0055","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1128\/AAC.02638-15","article-title":"Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae","volume":"60","author":"Shields","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0060","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/AAC.39.2.279","article-title":"Trimethoprim and sulfonamide resistance","volume":"39","author":"Huovinen","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0065","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-sixth informational supplement. Document M100-S26","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0070","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2016"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0075","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/jac\/13.4.400","article-title":"Cerebrospinal fluid penetration of trimethoprim\u2013sulphamethoxazole in two patients with Gram-negative bacillary meningitis","volume":"13","author":"Levitz","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0080","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1378\/chest.72.6.794","article-title":"Endocarditis due to Pseudomonas aeruginosa in a heroin addict. Successful treatment with trimethoprim\u2013sulfamethoxazole mixture plus colistin","volume":"72","author":"Yoshikawa","year":"1977","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0085","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/320532","article-title":"Resistance to trimethoprim\u2013sulfamethoxazole","volume":"32","author":"Huovinen","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0090","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim\u2013sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0095","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","article-title":"Trimethoprim\u2013sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection","volume":"117","author":"Markowitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0100","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijantimicag.2013.05.002","article-title":"Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim\/sulfamethoxazole and clindamycin\u2014preliminary report","volume":"42","author":"Casalta","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0105","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1345\/aph.1R211","article-title":"Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2\u2009\u00b5g\/mL to vancomycin: old (trimethoprim\/sulfamethoxazole) versus new (daptomycin or linezolid) agents","volume":"46","author":"Campbell","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0110","doi-asserted-by":"publisher","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim\u2013sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0115","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/jac\/dku352","article-title":"Randomized non-inferiority trial to compare trimethoprim\/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection","volume":"70","author":"Harbarth","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0120","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/ebmed-2015-110241","article-title":"Trimethoprim\u2013sulfamethoxazole monotherapy should not be used for treatment of severe methicillin-resistant Staphylococcus aureus infections","volume":"20","author":"Harbarth","year":"2015","journal-title":"Evid Based Med"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0125","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.diagmicrobio.2013.01.021","article-title":"Daptomycin plus trimethoprim\/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant Staphylococcus epidermidis","volume":"76","author":"Vena","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0130","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.transproceed.2016.01.060","article-title":"Successful treatment of urinary tract infection in kidney transplant recipients caused by multiresistant Klebsiella pneumoniae producing New Delhi metallo-\u03b2-lactamase NDM-1 with strains genotyping","volume":"48","author":"Wilkowski","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0135","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijantimicag.2015.04.002","article-title":"Trimethoprim\/sulfamethoxazole for Acinetobacter spp.: a review of current microbiological and clinical evidence","volume":"46","author":"Falagas","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0140","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-007460","article-title":"Trimethoprim\/sulfamethoxazole induced multiorgan dysfunction","volume":"2012","author":"Lee","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0145","article-title":"A case of drug-induced lupus erythematosus secondary to trimethoprim\/sulfamethoxazole presenting with pleural effusions and pericardial tamponade","author":"Jose","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0150","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/jac\/dks030","article-title":"Acute kidney injury associated with trimethoprim\/sulfamethoxazole","volume":"67","author":"Fraser","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0155","doi-asserted-by":"publisher","first-page":"727","DOI":"10.4065\/74.7.727","article-title":"The tetracyclines","volume":"74","author":"Smilack","year":"1999","journal-title":"Mayo Clin Proc"},{"issue":"Suppl. 6","key":"10.1016\/j.ijantimicag.2016.11.020_bib0160","article-title":"A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections","volume":"59","author":"Ritchie","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 6","key":"10.1016\/j.ijantimicag.2016.11.020_bib0165","article-title":"Carbapenem-resistance in Gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center","volume":"59","author":"Pogue","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 6","key":"10.1016\/j.ijantimicag.2016.11.020_bib0170","article-title":"Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options","volume":"59","author":"Castanheira","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0175","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ijantimicag.2015.09.008","article-title":"In vitro activity of \u2018old antibiotics\u2019 against highly resistant Gram-negative bacteria","volume":"46","author":"Dubourg","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 6","key":"10.1016\/j.ijantimicag.2016.11.020_bib0180","article-title":"Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections","volume":"59","author":"Goff","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0185","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/0885066610377975","article-title":"Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"25","author":"Chan","year":"2010","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0190","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.166.3901.122","article-title":"Phosphonomycin, a new antibiotic produced by strains of Streptomyces","volume":"166","author":"Hendlin","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0195","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0200","article-title":"Clinical efficacy of fosfomycin for the treatment of complicated lower tract and uncomplicated urinary tract infections","volume":"8","author":"Nagel","year":"2015","journal-title":"Int Arch Med"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0205","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0210","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12091","article-title":"Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge","volume":"19","author":"Navarro-San Francisco","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0215","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0220","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/cid\/ciu580","article-title":"Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial","volume":"59","author":"del Rio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0225","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Miro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0230","doi-asserted-by":"publisher","first-page":"e006723","DOI":"10.1136\/bmjopen-2014-006723","article-title":"Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial","volume":"5","author":"Shaw","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0235","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijantimicag.2011.11.012","article-title":"Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin","volume":"39","author":"Apisarnthanarak","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0240","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0245","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","article-title":"Adverse events associated with intravenous fosfomycin","volume":"37","author":"Florent","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0250","first-page":"4079","article-title":"The effect of fosfomycin on the respiration of rat kidney mitochondria","volume":"69","author":"Bendirdjian","year":"1978","journal-title":"Minerva Med"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0255","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0260","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.idc.2016.02.005","article-title":"Agents of last resort: polymyxin resistance","volume":"30","author":"Kaye","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0265","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S1473-3099(15)00533-2","article-title":"Dissemination of the mcr-1 colistin resistance gene","volume":"16","author":"Hu","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0270","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0275","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jac\/dkr007","article-title":"Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae","volume":"66","author":"Meletis","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0280","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1128\/AAC.05028-11","article-title":"Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula","volume":"55","author":"Bergen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0285","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1517\/14740338.2015.1088520","article-title":"The safety of polymyxin antibiotics","volume":"14","author":"Kelesidis","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0290","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1586\/14787210.2015.1070097","article-title":"Strategies for the safe use of colistin","volume":"13","author":"Ortwine","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0295","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0300","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1128\/AAC.00839-16","article-title":"In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii","volume":"60","author":"Bae","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.020_bib0305","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T18:23:15Z","timestamp":1536085395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0924857917300146"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.020","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}